Epidermolysis bullosa therapeutics market
Epidermolysis Bullosa Market, by Product Type (Antibiotics, Analgesics, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
- Jan 2023
- CMI2214
- 154 Pages
- Excel & Pdf
- Pharmaceutical
Epidermolysis bullosa is a group of rare inherited skin disorders that causes the skin to become very fragile. Any trauma or friction to the skin can cause painful blisters. The symptoms of epidermolysis bullosa include skin that blisters easily, blisters on hands and soles of the feet, thickened skin that may be scarred or change color over time, and thickening of the skin and nails.
There are three types of epidermolysis bullosa which includes:
- Epidermolysis bullosa simplex (EBS) – the most common type, which can range from mild, with a low risk of serious complications to severe
- Dystrophic epidermolysis bullosa (DEB) – which can range from mild to severe
- Junctional epidermolysis bullosa (JEB) – a rare form of epidermolysis bullosa that ranges from moderate to severe
The type reflects where on the body the blistering takes place and which layer of skin is affected.
Global epidermolysis bullosa market is estimated to be valued at US$ 3,429.30 million in 2022 and is expected to exhibit a CAGR of 11.2% over the forecast period (2022-2030)
Figure 1. Global Epidermolysis Bullosa Market Value (US$ Mn), By Region, 2022
Increasing prevalence of epidermolysis bullosa is expected to drive growth of the global epidermolysis bullosa market over the forecast period.
For instance, according to the data published in the Orphanet Journal of Rare Diseases in 2020, the overall prevalence of epidermolysis bullosa in the U.S. is 11.1 per million live births with an incidence of 1 in every 51,000 live births.
Figure 2. Global Epidermolysis Bullosa Market Share (%), By Product Type, 2022
Global Epidermolysis Bullosa Market Drivers
Increasing clinical trials for the treatment of epidermolysis bullosa is expected to propel the market growth over the forecast period.
For instance, on July 25, 2022, InMed Pharmaceuticals, Inc., which is involved in the research, development, manufacturing, and commercialization of rare cannabinoids INM-755 cannabinol cream for epidermolysis bullosa, provided an update that adolescent patients can participate in the clinical trial.
Moreover, on February 22, 2019, Phoenix Tissue Repair, Inc., a biotechnology company focused on developing a disease-modifying treatment for Dystrophic Epidermolysis Bullosa (DEB), announced that the first patient had been dosed in phase 1/2, first-in-human trial of PTR-01, a protein replacement therapy for recessive DEB.
Epidermolysis Bullosa Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2021 | Market Size in 2022: | US$ 3,429.30 Mn |
Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
Forecast Period 2022 to 2030 CAGR: | 11.2% | 2030 Value Projection: | US$ 8,008.50 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Global Epidermolysis Bullosa Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2020. According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, over 633,263,617 cases of coronavirus disease (COVID-19) were reported till November 15, 2022, across the globe.
The COVID-19 pandemic caused major disruptions to clinical trial execution in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, CROs (clinical research organizations), and other organizations that support drug development shifted to remote working environments. According to Lancet, an estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic.
Global Epidermolysis Bullosa Market Restraint
The high treatment cost of epidermolysis bullosa is expected to hinder the market growth over the forecast period.
For instance, according to the data published in the National Center for Biotechnology Information on September 8, 2020, the average monthly bandage cost epidermolysis bullosa range from US$ 262 to > US$ 2,000.
Key Players
Major players operating in the global epidermolysis bullosa market include Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- PEST Analysis
- Regulatory Scenario
- Market Trends
- Key Highlights
- Mergers & Acquisitions
- Market Dynamics
- Global Epidermolysis Bullosa Market – Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- Impact on Clinical Trials
- Government Initiatives
- Global Epidermolysis Bullosa Market, By Product Type, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Antibiotic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Analgesic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Introduction
- Global Epidermolysis Bullosa Market, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Introduction
- Global Epidermolysis Bullosa Market, By Region, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2030
- North America
- Market Size and Forecast, By Product Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Product Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Product Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Product Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 – 2030, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Amryt Pharma
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Abeona Therapeutics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Castle Creek Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- RegeneRx
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Krystal Biotech
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- RHEACELL GmbH
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Holostem Terapie Avanzate
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- StemRim/Shionogi
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Phoenix Tissue Repair
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Amryt Pharma
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
*Browse 53 market data tables and 38 figures on "Epidermolysis Bullosa Market” - Global forecast to 2030.
Detailed Segmentation:
- Global Epidermolysis Bullosa Market, By Product Type:
- Antibiotic
- Analgesics
- Others
- Global Epidermolysis Bullosa Market, By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Epidermolysis Bullosa Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- By Country/Region
- North America
- Company Profiles
- Amryt Pharma.*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Abeona Therapeutics
- Castle Creek Pharmaceuticals
- RegeneRx
- Krystal Biotech
- RHEACELL GmbH
- Holostem Terapie Avanzate
- StemRim/Shionogi
- Phoenix Tissue Repair
- Amryt Pharma.*
“*” marked represents similar segmentation in other categories in the respective section.